The estimated Net Worth of Yujiro S Hata is at least $27.8 Milion dollars as of 14 May 2024. Mr. Hata owns over 175,000 units of IDEAYA Biosciences stock worth over $25,785,984 and over the last 9 years he sold IDYA stock worth over $0. In addition, he makes $2,020,990 as President, Chief Executive Officer a Director at IDEAYA Biosciences.
Yujiro has made over 9 trades of the IDEAYA Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 175,000 units of IDYA stock worth $754,250 on 14 May 2024.
The largest trade he's ever made was exercising 175,000 units of IDEAYA Biosciences stock on 14 May 2024 worth over $754,250. On average, Yujiro trades about 18,784 units every 65 days since 2015. As of 14 May 2024 he still owns at least 712,320 units of IDEAYA Biosciences stock.
You can see the complete history of Mr. Hata stock trades at the bottom of the page.
Yujiro S. Hata serves as President, Chief Executive Officer, Director of the Company. He launched IDEAYA Biosciences, Inc. as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures, a venture capital firm, from 2015 to 2018. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, Inc., or Flexus, and FLX Bio, Inc., or FLX Bio, both immuno-oncology companies, which he joined as startups and led through Flexus’ acquisition by Bristol-Myers Squibb Co., or Bristol-Myers Squibb, in April 2015. From 2010 until its acquisition by Amgen Inc., or Amgen, in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, Inc. where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Mr. Hata served as Vice President and Senior Vice President of Business Development, and Chief Business Officer at Enanta Pharmaceuticals, Inc. He earlier served in oles at McKinsey & Company, ImClone Systems Incorporated, and Columbia Medical School. He serves on the board of directors at Xencor, Inc. Mr. Hata obtained an M.B.A. at The Wharton School at the University of Pennsylvania and a B.A. in Chemistry from Colorado College.
As the President, Chief Executive Officer a Director of IDEAYA Biosciences, the total compensation of Yujiro Hata at IDEAYA Biosciences is $2,020,990. There are no executives at IDEAYA Biosciences getting paid more.
Yujiro Hata is 46, he's been the President, Chief Executive Officer a Director of IDEAYA Biosciences since 2015. There are 15 older and 3 younger executives at IDEAYA Biosciences. The oldest executive at IDEAYA Biosciences, Inc. is Wendy Yarno, 65, who is the Independent Director.
Yujiro's mailing address filed with the SEC is C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at IDEAYA Biosciences have traded over $13,169,580 worth of IDEAYA Biosciences stock and bought 2,220,527 units worth $22,722,236 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Timothy M Shannon a X L.P.Canaan Partners X Llc.... On average, IDEAYA Biosciences executives and independent directors trade stock every 29 days with the average trade being worth of $2,196,906. The most recent stock trade was executed by Jason Throne on 27 June 2024, trading 53,484 units of IDYA stock currently worth $415,571.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences executives and other stock owners filed with the SEC include: